46 terminated. 46 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Terminated 46 |
| Phase 2 | 5 | Terminated 5 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial Placebo, ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 68 | 2024-12-20 | 2026-06-30 |
| The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 19 | 2024-07-23 | 2026-06-30 |
| Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese | Phase 2 / Phase 3 | Terminated | Xiaojun Chen | 8 | 2022-05-01 | 2026-06-04 |
| A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 4 | 2022-04-13 | 2023-10-19 |
| Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease | Phase 3 | Terminated | Geisinger Clinic | 15 | 2021-07-23 | 2024-02-09 |
| Balloon to Induce Labor in Generous Women. Balloon catheter + oral misoprostol, Oral misoprostol alone - Maternal Obesity | Phase 3 | Terminated | University Hospital, Toulouse | 429 | 2020-06-26 | 2023-05-15 |
| Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients Lorcaserin 10 mg BID, Matching Placebo BID - Obesity | Phase 3 | Terminated | Kanion & Huawe Medicine Co.,Ltd | 100 | 2019-09-17 | 2022-05-02 |
| Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 / Phase 3 | Terminated | Millendo Therapeutics SAS | 158 | 2019-03-25 | 2021-02-17 |
| The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients Dapagliflozin 10mg, Exenatide 2 mg [Bydureon], Placebo Oral Tablet - Obesity, Diabetes Mellitus, Type 2 | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 13 | 2018-02-19 | 2020-03-31 |
| Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery tranexamic acid, Placebo - Intra-Operative Injury - Other, Post Operative Hemorrhage | Phase 3 | Terminated | Sheba Medical Center | 152 | 2017-09-01 | 2023-04-19 |
| Randomization of Early Diabetes Screening Among Obese Pregnant Women. Screening for diabetes with 1-hour GCT and HbA1 - Gestational Diabetes | Phase 3 | Terminated | University of Illinois at Chicago | 600 | 2017-03-19 | 2020-03-03 |
| Addressing Post Cessation Weight Gain lorcaserin, Varenicline, Placebo - Obesity, Smoking Cessation | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 84 | 2016-06-15 | 2021-06-10 |
| Capsaicin Patches In Knee Osteoarthritis In Obese Patients capsaicin 8% patches (Qutenza), Placebo patches - Pain | Phase 3 | Terminated | Nadine ATTAL | 22 | 2015-07-01 | 2019-04-17 |
| Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity | Phase 3 | Terminated | Zafgen, Inc. | 108 | 2014-09-01 | 2017-01-26 |
| Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks Topiramate, Placebo Comparator - Prader-Willi Syndrome | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 69 | 2012-12-01 | 2018-04-11 |
| A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics PolyGlycopleX® - PGX®, Rice Flour (placebo) - Type II Diabetes Mellitus, Obesity | Phase 3 | Terminated | InovoBiologic Inc. | 100 | 2012-10-01 | 2021-02-11 |
| Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) NB32, PBO, Weight Management Program - Obesity, Overweight | Phase 3 | Terminated | Orexigen Therapeutics, Inc | 8910 | 2012-06-01 | 2017-02-27 |
| Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid GLP-1 (Liraglutide), Placebo - Obesity | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 2 | 2011-12-01 | 2022-06-30 |
| Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient Removal of surgical skin staples - Wound Complications, Obesity | Phase 2 / Phase 3 | Terminated | Prisma Health-Upstate | 292 | 2009-10-01 | 2021-03-17 |
| Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients rimonabant (SR141716) - Obesity, Weight Loss | Phase 3 | Terminated | Sanofi | 331 | 2008-04-01 | 2009-06-17 |
Showing 20 of 46. Sign in to see all of them.
Obesity (38) · Diabetes Mellitus, Type 2 (8) · Prader-Willi Syndrome (8) · Diabetes Mellitus (6) · Hyperphagia (5) · Weight Loss (4) · Dyslipidemias (3) · Body Weight (2) · Cardiovascular Diseases (2) · Obesity, Morbid (2) · Arteriosclerosis (1) · Carotid Artery Diseases (1) · Carotid Stenosis (1) · Diabetes, Gestational (1)
Nutritional and Metabolic Diseases (46) · Nutrition Disorders (45) · Overnutrition (45) · Pathological Conditions, Signs and Symptoms (45) · Signs and Symptoms (45) · Body Weight (39) · Metabolic Diseases (12) · Glucose Metabolism Disorders (11) · Endocrine System Diseases (10) · Nervous System Diseases (10) · Neurologic Manifestations (9) · Abnormalities, Multiple (8) · Chromosome Disorders (8) · Congenital Abnormalities (8)
Rimonabant (11) · N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide (4) · Topiramate (3) · lorcaserin (2) · Anastrozole (1) · BID protein, human (1) · CKD732 (1) · Caloric Restriction (1) · Capsaicin (1) · Diet (1) · Exenatide (1) · Exercise (1) · Flour (1) · Glucagon-Like Peptide 1 (1) · Glycated Hemoglobin (1)
Sanofi (10) · Merck Sharp & Dohme LLC (4) · Pfizer (4) · Aardvark Therapeutics, Inc. (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Universitätsklinikum Hamburg-Eppendorf (2) · Abbott (1) · Assistance Publique - Hôpitaux de Paris (1) · C. R. Bard (1) · Children's Heart Center (1) · Geisinger Clinic (1) · InovoBiologic Inc. (1) · Kanion & Huawe Medicine Co.,Ltd (1) · Mayo Clinic (1) · Millendo Therapeutics SAS (1)
United States (20) · United Kingdom (10) · Canada (9) · France (9) · Australia (8) · Germany (7) · Netherlands (7) · Spain (6) · Finland (5) · Sweden (5) · Czechia (4) · Hungary (4) · Italy (4) · Mexico (4) · South Korea (4)
Jens Aberle, MD (2) · Ahmad O Hammoud, MD (1) · Alex R Chang, MD, MS (1) · Alexandra Kautzky-Willer, Prof. Dr. (1) · Andreas Fritsche, Prof. Dr. (1) · Christophe Vayssiere, Pr (1) · Claire Carette (1) · Deepak L. Bhatt, MD (1) · Dennis Kim, MD (1) · Eric Topol, MD (1)
PMID 20157323, PMID 20379151, PMID 20709233, PMID 20965292, PMID 20976246, PMID 21610270, PMID 23567348, PMID 25077901, PMID 26954408, PMID 28556449, PMID 32642971, PMID 36160639, PMID 36996264
2005 (2), K23DA037299 (1)